epz005687 and Lymphoma

epz005687 has been researched along with Lymphoma* in 2 studies

Other Studies

2 other study(ies) available for epz005687 and Lymphoma

ArticleYear
Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Journal of medicinal chemistry, 2014, Nov-26, Volume: 57, Issue:22

    Polycomb Repressive Complex 2 (PRC2) modulates the chromatin structure and transcriptional repression by trimethylation lysine 27 of histone H3 (H3K27me3), a process that necessitates the protein-protein interaction (PPI) between the catalytic subunit EZH2 and EED. Deregulated PRC2 is intimately involved in tumorigenesis and progression, making it an invaluable target for epigenetic cancer therapy. However, until now, there have been no reported small molecule compounds targeting the EZH2-EED interactions. In the present study, we identified astemizole, an FDA-approved drug, as a small molecule inhibitor of the EZH2-EED interaction of PRC2. The disruption of the EZH2-EED interaction by astemizole destabilizes the PRC2 complex and inhibits its methyltransferase activity in cancer cells. Multiple lines of evidence have demonstrated that astemizole arrests the proliferation of PRC2-driven lymphomas primarily by disabling the PRC2 complex. Our findings demonstrate the chemical tractability of the difficult PPI target by a small molecule compound, highlighting the therapeutic promise for PRC2-driven human cancers via targeted destruction of the EZH2-EED complex.

    Topics: Astemizole; Binding, Competitive; Catalysis; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Enhancer of Zeste Homolog 2 Protein; Histones; Humans; Lymphoma; Magnetic Resonance Spectroscopy; Methylation; Models, Molecular; Molecular Docking Simulation; Neoplasms; Polycomb Repressive Complex 2; Protein Interaction Mapping; Protein Processing, Post-Translational

2014
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Nature chemical biology, 2012, Volume: 8, Issue:11

    EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27). Point mutations of EZH2 at Tyr641 and Ala677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation. Here we report the discovery of EPZ005687, a potent inhibitor of EZH2 (K(i) of 24 nM). EPZ005687 has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1. The compound reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr641 or Ala677 mutant cells, with minimal effects on the proliferation of wild-type cells. These data suggest that genetic alteration of EZH2 (for example, mutations at Tyr641 or Ala677) results in a critical dependency on enzymatic activity for proliferation (that is, the equivalent of oncogene addiction), thus portending the clinical use of EZH2 inhibitors for cancers in which EZH2 is genetically altered.

    Topics: Antineoplastic Agents; Cell Cycle; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Lymphoma; Lysine; Methylation; Molecular Structure; Point Mutation; Polycomb Repressive Complex 2; Pyridones; Structure-Activity Relationship

2012